VEGF gene therapy: Stimulating angiogenesis or angioma-genesis?

Nature Medicine

Volumn 6, Issue 10, 2000, Pages 1102-1103

  Carmeliet, P ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ALLELE; ANGIOGENESIS; ANGIOMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; CAUSE OF DEATH; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HEART MUSCLE CELL; HEMANGIOMA; MOTONEURON; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION; GENE THERAPY; HEART; HEART NEOPLASMS; HEMANGIOMA; HUMAN; LYMPHOKINES; MICE; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0033793881     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/80430     Document Type: Short Survey

References (14)

1. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression
2. Abnormal blood vessel development and lethality in embryos lacking a single vascular endothelial growth factor allele
3. Clinical applications of angiogenic growth factors and their inhibitors
4. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
5. VEGF is required for growth and survival in neonatal mice
6. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121
7. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF 165 in patient with ischaemic limb
8. Angiopoietin-1 protects the adult vasculature against plasma leakage
9. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults
10. A novel means of drug delivery: Myoblast-mediated gene therapy and regulatable retroviral vectors
11. Mechanisms of angiogenesis and arteriogenesis
12. Heterogeneity of the angiogenie response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
13. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
14. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice